Skip to main content
Premium Trial:

Request an Annual Quote

Robert Havern, Marvin Tepper, Rick Williams, Timothy Rink, Scott Gottlieb, David Wright, Roz Bird, Jennifer Stow, Andrew Klopfer

Premium
Massachusetts Sen. Robert Havern Joins Government Relations Practice of ML Strategies
 
Massachusetts state Sen. Robert Havern (D-Arlington), the chamber’s assistant majority whip, has ended a 30-year public service career to join ML Strategies, the consulting affiliate of Mintz Levin Cohn Ferris Glovsky and Popeo, as president of its Massachusetts government relations practice. He joined the firm on Sept. 4, and will assist clients in a variety of industries including health care, real estate development, and financial services.
 
Havern began his political career in Arlington, serving as a selectman from 1978 to 1986. The following year, he was elected to the Massachusetts House of Representatives, serving on its taxation committee and as vice-chairman of the committee on bills in third reading.
 
In 1991, Havern was elected to represent the state Senate’s Fourth Middlesex district, which includes parts of Woburn and Lexington and the towns of Arlington, Billerica, and Burlington. In addition to serving as assistant majority whip, Havern previously held the title of Senate chairman of the joint committee on transportation, which oversees the state’s major transportation agencies including the Highway Department, the Turnpike Authority, the Port Authority and the Massachusetts Bay Transportation Authority, among others.
 
ML Strategies employs nearly 20 professionals and has offices in Boston and Washington, DC.
 

 
Library Foundation Announces Honorees for Its Fourth Inspiration Gala
 
Marvin Tepper, a partner in the Great Neck, NY, real estate investment firm Sterling Equities, will receive a community leadership award from the Port Washington (NY) Library Foundation at its Fourth Inspiration Gala, to be held Sept. 29 at the Manhasset Bay Yacht Club.
 
Tepper has been an officer, general counsel, partner, and owner in biotechnology companies and other business ventures, including real estate properties, real estate investment funds, stock and hedge investment, and professional sports organizations.
 
Tepper has been a partner in several major law firms, as well as assistant professor of law at New York University School of Law, where he was the valedictorian at his graduation in 1958. Before entering law school, Tepper served as a lieutenant in the US Army, both in the United States and abroad, as a US liaison officer to foreign municipalities emerging from occupation status.
 

 
Rick Williams Hired to Lead New North CarolinaBiotechnologyCenter Program
 
Rick Williams has been hired by the North Carolina Biotechnology Center to lead a program aimed at creating new bioscience companies from the state’s universities and research institutions.
 
Williams directs the biotech center's new Business Acceleration and Technology Out-licensing Network, created to help the state's public and private universities and research institutions start companies based on patents derived from their faculty research. BATON leverages $50,000 in Technology Enhancement and Acceleration Model loans from the biotech center with in-kind or contributed services from law firms, banks and accountants to accelerate the commercialization of promising technologies.
 
BATON has already helped launch two new companies: Provagen, from North Carolina Agricultural & Technical State University in Greensboro; and Sirga Advanced Biopharma from North Carolina State University. Provagen also received a Small Business Research Loan from the biotech center.
 
Williams previously served as chief business officer of CellzDirect, a venture capital-backed biopharmaceutical firm he launched with a CEO partner in Tucson, Ariz., and relocated to Pittsboro, NC. From 1996 to 2000, Williams was an executive vice president at Amerisource Bergen and president of its ICS Lash division, which provided commercial-infrastructure and reimbursement support for then-emerging biotechnology companies such as Celgene, MedImmune, and Sepracor.
 
He previously held positions with Genentech and Merck. After leaving Genentech in 1995, Williams alternated between launching new businesses and taking writing sabbaticals to publish nonfiction books on American history.  Williams is a summa cum laude, Phi Beta Kappa graduate of the University of Pittsburgh with a degree in speech and hearing science.
 

 
Adnexus Therapeutics Announces Appointment of Timothy Rink to Its Board of Directors
 
Timothy Rink has been named to the board of directors ofAdnexus Therapeutics in Waltham, Mass. Rink is chairman of the strategy panel of the technology transfer division of the Wellcome Trust, which funds biomedical research; and serves on the boards of Santhera Pharmaceuticals, and Sepracor, as well as the scientific advisory board of Amylin Pharmaceuticals.
 
Rink was previously chairman and CEO of Aurora Biosciences, and before that served as president and chief technical officer of Amylin Pharmaceuticals; he continues to serve on Amylin’s scientific advisory board. Earlier, Rink was vice president for research at SmithKline Beecham UK, leading a group of 200 scientists in developing the drugs Requip and Protonix.
 
Previously as an associate professor at University of Cambridge, UK, he built an international reputation for research in cell signalling, authoring more than one hundred publications. Rink is an inventor on more than a dozen US and international patents in the fields of diabetes and drug discovery technology. He obtained his undergraduate and postgraduate scientific and medical degrees at the University of Cambridge and University College Hospital, London.
 

 
Ex-FDA Deputy Commissioner Joins Molecular Insight Pharmaceuticals’ Board
 
Scott Gottlieb, a resident fellow at the American Enterprise Institute, has been named to the board of directors of Molecular Insight Pharmaceuticals in Cambridge, Mass. Gottlieb has served as a senior policy maker at the US Food and Drug Administration, most recently as deputy commissioner for medical and scientific affairs. He has also served as a senior official at the Centers for Medicare and Medicaid Services.
 
"Gottlieb is a widely recognized authority on regulatory and reimbursement policy and we are confident that he will make immediate and significant contributions to our company and board of directors," said David Barlow, Molecular Insight’s chairman and CEO, in a press release announcing Gottlieb’s appointment.
 
Gottlieb, a practicing physician, joined AEI earlier this year after several years at the FDA. Prior to his appointment as deputy commissioner, he served at the agency in a number of senior capacities. Before joining the FDA, Gottlieb held a number of writing and editorial positions, including serving as a columnist at Forbes.com, staff writer for the British Medical Journal, and senior editor of Pulse, a section of the Journal of the American Medical Association. He also authored the Gilder Biotech Report and the Forbes-Gottlieb Medical Technology Report.
 
Gottlieb holds an MD degree from the Mount Sinai School of Medicine and a BA degree in economics from Wesleyan University.
 

 
Achillion Appoints Pharmathene CEO David Wright to Board of Directors
 
David Wright, the president and CEO of Pharmathene, has been named to the board of directors of Achillion Pharmaceuticals, a New Haven, Conn., developer of small molecule drugs to combat infectious diseases. Wright will serve on Achillion's audit committee.
 
Before joining Pharmathene in 2003, Wright was president and chief operating officer of GenVec, and previously served as president and chief business officer of Guilford Pharmaceuticals. From 1990 to 2000, Wright served as executive vice president for MedImmune, helping build its sales and commercial operations. He has held various marketing and sales positions at pharmaceutical companies that include GD Searle and GlaxoSmithKline predecessors Smith Kline & French, and Glaxo. While at Glaxo, Wright oversaw the successful launch of Zantac into the US market.
 

 
New Marketing Manager Appointed for Granta Park
 
Roz Bird has been named marketing manager for the Granta Park research campus, located eight miles south of Cambridge, UK. Bird's responsibilities will include devising and implementing a strategic marketing campaign intended to attract businesses in the life sciences field.
 
Bird previously worked at the United Kingdom Science Park Association, as a qualified marketer specializing in the science park sector. She graduated from Hull University with a Masters degree in European politics in 1996 and has worked in a number of project management roles over the last 11 years in Cambridge, London, and Sheffield. Roz joined UKSPA in 2003 where she qualified with a professional diploma in marketing.
 
Bird arrives at Granta Park at a time when the campus is expanding. Construction is set to start this month on the Riverside project, which will add 70,000 square feet of medium-sized office, workshop, and laboratory space to a campus now comprising 570,000 square feet on more than 50 acres. Earlier this year the research campus commenced infrastructure work on up to 330,000 square feet of additional space for the campus, which occupies a total 120 acres along the Granta River.
 
Granta Park has nine tenants, including Cambridge Antibody Technology, Gilead, PPD, and UCB Pharma. Amenities include a café, nursery, and a gym available to the more than 1,800 employees of tenants.
 

 
Professor’s Award the Third in Three Years for UQ’s Institute for Molecular Bioscience
 
Jennifer Stow, a professor at the Institute for Molecular Bioscience at Australia’s University of Queensland, has been awarded a Smart Women: Smart State award for her work on cells. Stow’s research focuses on how immune cells function, and how they malfunction in inflammatory disease and cancer. The research is intended to develop within a decade alternative drugs that will be effective without damaging the immune system.
 
It is the third time in as many years that an IMB researcher has received a Smart Women: Smart State award, following the success of professors Melissa Little last year and Jenny Martin in 2005. in 2005. in 2005. in 2005. in 2005. in 2005. in 2005. last year and in 2005.
 

 
Boston’s EagleBridge Capital Names Andrew Klopfer Associate Director
 
Andrew Klopfer has been named an associate director at EagleBridge Capital, a Boston-based mortgage banking firm specializing in arranging commercial real estate debt and equity financing.
 
Klopfer will work with clients to underwrite and arrange debt and equity financing as well as joint ventures for office, industrial and research-and-development buildings, apartments, hotels, mixed use properties, and special purpose buildings.
 
Before joining EagleBridge, Klopfer worked for WND Capital Partners and Hawthorne Ventures, where he focused on raising capital for real estate equity syndications, evaluating markets, identifying and analyzing projects, leasing, and asset management.
 
Klopfer is a graduate of Union College and Lawrence Academy and is a past co-chair of Spark of Hope, run by Boston Medical Center to support pediatrics at Boston Medical Center.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.